Toyama, Japan

Masaaki Shibata


Average Co-Inventor Count = 8.5

ph-index = 2

Forward Citations = 112(Granted Patents)


Company Filing History:


Years Active: 1983-1992

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Masaaki Shibata: Innovator in Antitumor Agents

Introduction

Masaaki Shibata is a notable inventor based in Toyama, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antitumor agents. With a total of 2 patents to his name, Shibata's work focuses on innovative compounds that exhibit promising therapeutic effects.

Latest Patents

Shibata's latest patents include the development of isoindole derivatives and salts thereof, which demonstrate excellent antitumor activity with low toxicity. One of his notable inventions is a novel isoindole derivative represented by a specific general formula, which has shown potential in cancer treatment. Additionally, he has developed a carcinostatic and immunostimulating agent that contains lysophospholipid and phospholipid. This agent is designed for the treatment of cancerous diseases in mammals, including humans, and encompasses a process for its preparation and application.

Career Highlights

Masaaki Shibata is associated with Toyama Chemical Co., Ltd., where he continues to advance his research in pharmaceutical innovations. His work has contributed to the understanding and treatment of cancer, making a significant impact in the medical field.

Collaborations

Shibata has collaborated with esteemed colleagues such as Yutaka Kodama and Kaoru Oyama. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Masaaki Shibata's contributions to the field of antitumor agents highlight his innovative spirit and dedication to improving cancer treatment. His patents reflect a commitment to advancing medical science and providing effective solutions for cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…